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Abstract 23 
This review summarizes the evidence for the potential involvement of metabotropic 24 
glutamate receptor 5 (mGluR5) in the development of nicotine addiction. Nicotine is 25 
consumed worldwide and is highly addictive. Previous research has extensively investigated 26 
the role of dopamine in association with reward learning and addiction, which has provided 27 
strong evidence for the involvement of dopaminergic neuronal circuitry in nicotine addiction. 28 
More recently, researchers focused on glutamatergic transmission after nicotine abuse, and its 29 
involvement in the reinforcing and rewarding effects of nicotine addiction. A number of 30 
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robust preclinical and clinical studies have shown mGluR5 signaling as a facilitating 31 
mechanism of nicotine addiction and nicotine withdrawal. Specifically, clinical studies have 32 
illustrated lower cortical mGluR5 density in smokers compared to non-smokers in the human 33 
brain. In addition, mGluR5 might selectively regulate craving and withdrawal. This suggests 34 
that mGluR5 could be a key receptor in the development of nicotine addiction and therefore 35 
clinical trials to examine the therapeutic potential of mGluR5 agents could help to contribute 36 
to reduce nicotine addiction in society. 37 
 38 
Abbreviations: mGLuR5 - metabotropic glutamate receptor 5, mGLuR - metabotropic 39 
glutamate receptor, iGLuR – ionotropic glutamate receptor, DA – Dopamine, NAc – Nucleus 40 
Accumbens.  41 
Epidemiology of Nicotine Addiction 42 
Nicotine addiction is one of the most common and preventable chronic psychiatric 43 
conditions characterised by the compulsion to seek and use nicotine 
1
. Worldwide, there are 44 
approximately 1.1 billion adult smokers and 80 % of them live in low- and middle- income 45 
countries 
2
. More than 7 million smokers die each year because of smoking related diseases, 46 
around 890,000 of which are being exposed to second-hand smoke (i.e. indirect exposure to 47 
smoke exhaled by smokers) 
3
 . Stopping nicotine consumption can lead to significant 48 
withdrawal symptoms for instance, depressed mood, attention/concentration problems, 49 
anhedonia, cravings, dysphoria, anxiety, irritability, and somatic problems (such as insomnia 50 
and weight gain) 
1,4
. In the USA, about 40 – 50 % of smokers try to stop smoking every year, 51 
however, only about 6 % are able abstain for at least 6 to 12 months 
5
. The majority of 52 
relapses happen within the first week of abstinence, with 15 – 28 % of smokers staying 53 
abstinent for 1 month, 10 - 20% remaining abstinent 3 months, and 3 – 5 % for 6 months 
6
. 54 
The longer a smoker stays abstinent, the better the chances that the abstinence will sustain. A 55 
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study measuring success rates found that only 12% of smokers who stopped smoking for one 56 
month remained abstinent at the follow up stage (i.e., 1.5 years). Of those who stayed 57 
abstinent for 1 – 3 months, 25% remained abstinent long term. A long term success rate of 58 
52% could be found in smokers who stayed abstinent for 3 – 6 months, again suggesting that 59 
the longer the initial abstinence period, the greater the probability of long-term abstinence 
7
. 60 
Therefore, due to these low abstinence rates it is necessary to find new pharmacotherapeutic 61 
options for nicotine addiction which could enhance abstinence rates. 62 
 63 
The glutamate system and nicotine addiction 64 
Glutamate is the major excitatory neurotransmitter in the central nervous system and is 65 
produced from glutamine by the enzyme glutaminase, which is localized in neurons and glia 
8
. 66 
Over 90% of the synapses in the human brain are glutamatergic. Glutamate has the opposite 67 
effect to the neurotransmitter of Gamma Aminobutyric Acid (GABA), which is one of the 68 
main inhibitory neurotransmitters of the central nervous system. Numerous authors have 69 
suggested that glutamate signalling in the brain plays a major role in the nicotine addiction 70 
9,10,11
. Furthermore, glutamate neurotransmission in the CNS is involved in various disorders 71 
such as schizophrenia, depression, addiction, and neurodegenerative diseases, such as 72 
Alzheimer's, Parkinson's and multiple sclerosis 
11,12,13
. Glutamate signalling activates its 73 
receptors, which are categorized in two large groups: the metabotropic glutamate receptors 74 
(mGluRs) and ionotropic glutamate receptors (iGluRs). Fast acting ionotropic (iGlu) receptors 75 
include N-methyl-D-aspartate receptor (NMDA), α-amino-3-hydroxy-5-methyl-4-76 
isoxazolepropionic acid receptor (AMPA) and kainate. Slow acting metabotropic receptors 77 
involve the mGluR1-8. They are predominantly localized on postsynaptic as well as on glia 78 
cells in the brain, coupled with a G- protein. The mGlu receptors are classified into three 79 
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groups; Group I receptors (mGluR1 and mGluR5), Group II receptors (mGluR2 and mGluR3) 80 
and Group III receptors (mGluR4, mGluR6, mGluR7 and mGluR8) 
8
. 81 
Several preclinical studies have found that nicotine increases glutamatergic 82 
transmission through activation of nicotinic acetylcholine receptor (nAChRs) located on 83 
glutamatergic afferents in the ventral tegmental area (VTA) and the nucleus accumbens 84 
(NAc) 
14
 (see Figure 1 for depiction of this action). Furthermore, long-term nicotine exposure 85 
could cause changes in dopamine and glutamate systems 
8
 For example, it was found that 86 
nicotine injections enhanced the brains reward function in rats as measured through 87 
intracranial self-administration 
15
. Nicotine dependence is the result of a positive effect of 88 
nicotine, specifically, it induces a dopamine (DA) increase in NAc. DA extracellular overflow 89 
is subsequently implicated in behavioural motivation and dependence, as it activates the 90 
reward system. Indeed, there is evidence that chronic nicotine administration can lead to a 91 
reduction of glutamate transmission in the meso-cortico-limbic system, mainly in NAc and 92 
VTA 
8,16
. Early withdrawal symptoms in rats following chronic nicotine administration, was 93 
associated with decreased glutamate transmission and compensatory changes in glutamate 94 
receptors 
16
.  95 
More recently, using Magnet Resonance Spectroscopy (MRS) in humans, the 96 
glutamatergic systems in nicotine addicted participants was investigated. The researchers 97 
found that smoking led to lower glutamate levels in the anterior cingulate cortex (ACC) and 98 
prefrontal cortex (PFC) 
17
 regions associated with reward processes. In another MRS study, 99 
glutamate levels in the thalamus were compared between smokers and non-smokers, showing 100 
lower thalamic glutamate in smokers 
18
.  101 
Pharmacological interventions targeting the glutamate system have been used to 102 
discover novel therapeutic treatments for smokers. N- acetylcysteine is traditionally used as a 103 
mucolytic in chronic obstructive pulmonary disorder. It is a precursor of L-cysteine that has 104 
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the ability to enhance glutamate transmission and restore the reduced glutamate level caused 105 
by nicotine addiction 
19,20,21
. Studies have shown that treatment with N-acetylcysteine led to 106 
participants reporting less withdrawal symptoms, decreasing their daily cigarette 107 
consumption, and significantly decreasing the reward effect of nicotine consumption 108 
compared to the control group 
22
. However, over time, about 50% of the participants relapsed 109 
20,23
.  110 
  111 
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Figure 1. The figure shows the processes leading to nicotine dependence. It shows that 114 
nicotine release, triggers an interaction with nAChRS on dopaminergic and glutamatergic 115 
neurons, particularly on mGlu5 receptor. Nicotine triggers the change of mGluR5 availability. 116 
It further illustrates the accumulating evidence suggesting that mGluR5 is significant in 117 
nicotine addiction. 118 
 119 
The role of mGluR5 in nicotine addiction in preclinical studies 120 
Metabotropic glutamate receptor 5 (mGluR5) belongs to the Group I metabotropic 121 
receptors and its actions are predominantly excitatory. Most mGluR5s are on postsynaptic 122 
neurons, but they are also found on presynaptic neurons, on glial cells, and on intracellular 123 
membranes with the ability to activate multiple cell signalling pathways. MGlu5 is a G 124 
protein-coupled receptor that activates phospholipase C, which produces diacyl glycerol and 125 
inositol triphosphate, which in turn increases calcium. Therefore, mGluR5 is responsible for 126 
Ca2
+
 fluctuations and regulates the activity of locomotor networks and neurotransmitter 127 
release. Recently, the extracellular signal-regulated kinase (ERK) as a downstream mediator 128 
of mGluR5 activity has been investigated in relation to addiction because of its role in 129 
synaptic plasticity, including maladaptive forms of plasticity associated with drug abuse 
24
.  130 
Furthermore, Calcium ions are one type of second messengers and the Ca2
+
 signalling 131 
pathway is a key component of the mechanisms that regulate neuronal excitability, 132 
information processing, and cognition, and it has been implicated in various neural diseases 133 
15,25,26
. A high density of mGluR5 can be found in several brain areas such as the forebrain, 134 
striatum, limbic system, amygdala, hippocampus, NAc, olfactory tubercle, and cerebral cortex 135 
26
. Furthermore, mGluR5 is critically implicated in normal and aberrant neuroplasticity and is 136 
involved in learning, motivation, motor coordination, reward behaviour, substance abuse, 137 
memory and emotion. Several recent reviews have suggested a potential association between 138 
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mGluR5 and nicotine addiction 
11,13,15
. In an mGluR5 knock out model study, it was 139 
suggested that this receptor is implicated in anhedonia and somatic signs of nicotine 140 
withdrawal 
27
. These findings are consistent with pharmacological studies showing mGluR5 141 
related signalling in nicotine addiction. In animal studies, rats who were treated acutely with 142 
nicotine (subcutaneously) showed increased levels of extracellular glutamate in the NAc 
28
 143 
and downregulation of mGluR5 expression 
8,14
. Such an inverse relationship between mGluR5 144 
and glutamate levels as determined by MRS have also been found in humans 
29
. In addition, 145 
intracellular interactions between protein kinases and metabotropic receptors in the striatum, 146 
might regulate behavioural changes in response to drug abuse 
30
. Specifically, repeated 147 
exposure to nicotine increased ERK phosphorylation in adult rats 
31
. 148 
Interestingly, pharmacological studies have found functional interactions of mGluR5 149 
with dopamine D1/D2, NMDA, adenosine A2, and GABA receptors 
11,13,15
. The mGlu5 150 
receptor was co-localised with dopamine and adenosine receptors in the striatum, including 151 
the NAc, where they are involved in the regulation of dopaminergic neurotransmission 
15,25
. 152 
More research is needed to understand the potential interactions between mGluR5 153 
signalling and dopaminergic neurotransmission in the reward system. It is established that 154 
dopamine and glutamate system are anatomically closely located in the meso-cortico-limbic 155 
area. These brain regions are important in the regulation of motivation behaviours and 156 
emotions. Researchers have shown the interaction between mGlu5 and DA receptors, with 157 
mGluR5 being involved in the regulation of DA release in the NAc 
15
. It can be suggested that 158 
mGluR5 plays a major role in the regulation of the reinforcing effects of nicotine through 159 
modulation of dopaminergic neurotransmission 
32
. The interaction of both systems suggests 160 
the importance for both; controlling addiction, and reward related behaviour in nicotine 161 
addiction, by demonstrating that the strong rewarding effect of dopamine overflow can be 162 
modulated by mGluR5 inhibition 
15
. Furthermore, the direct inhibition of NMDAR channels 163 
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are regulated by the mGlu5 receptors through the protein complex formed by Homer 
33
. 164 
Activation of NMDAR is responsible for long-term learning and memory and plays main role 165 




Therapeutical potential of mGluR5-NAMs in preclinical studies 168 
Several studies used negative allosteric mGlu5 receptor antagonists MTEP (3-((2-169 
Methyl-4-thiazolyl)ethynyl)pyridine) or MPEP (3-((2-Methyl-4-thiazolyl)ethynyl)pyridine) 170 
11,15
 to study the relevance of mGluR5 signalling in nicotine addiction. Prior treatment with 171 
MPEP (which inhibits the responding for nicotine) for 30 minutes resulted in a dose-172 
dependent reduction of nicotine self-administration while at the same time decreased 173 
extracellular DA level in NAc (Tronci & Balfour, 2011). Furthermore, pre-treatment with 174 
MPEP in rats inhibited responses to nicotine, suggesting MPEP inhibits nicotine seeking 175 
behaviour 
35
 Furthermore, the effect of MPEP administration in nicotine treated rats was 176 
highly significant compared to control, saline-treated rats. The response to nicotine in rats was 177 
greater if they were pre-treated with nicotine for eight days prior to the testing session 
36
. 178 
MPEP’s effect on nicotine consumption may be mediated by intracellular protein kinases such 179 
as ERK in the brain reward system 
31
. Mavoglurant and other medications (e.g. AZD2066, 180 
Basimglurant), which target mGluR5, have been examined in human research as an aid for 181 
nicotine cessation. However, these medications have the potential to cause some serious side 182 
effects in humans such as hallucinations, skin reactions and cognitive problems 
36
. MTEP and 183 
MPEP were shown to decrease nicotine intake, however, neither appeared to reduce the 184 
reward enhancing effects of nicotine. In an intravenous nicotine self-administration study, 185 
MPEP injection reduced self- administration in a dose dependent manner, while it did not 186 
alter general locomotion and lever pressing for sweetened food reward in rats 
35
. This could 187 
either indicate that food was a more rewarding treat than nicotine or a nicotine specific 188 
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involvement of mGluR5. MGluR-NAMs lead to a reduction of nicotine self-administration 189 
but have no influence on the motivation enhancing effect of nicotine 
36,37
. In a wide 190 
preclinical study, rats that received the pre-treatment with MPEP and were either non-191 
conditioned or operant conditioned to nicotine, showed that MPEP attenuated the reinforcing 192 
properties of nicotine. It suggests that the activity of mGlu5 receptors may play an important 193 
role in provoking drug-seeking behaviour and nicotine cravings in habitual smokers exposed 194 
to cues associated with their smoking habit 
35
. In addition, pre-treating rats with dose 195 
dependent MPEP, nicotine causes attenuated DA overflow in the NAc 
15,35
. It is therefore 196 
hypothesised that mGluR5 antagonists downregulate the increasing extracellular DA from 197 
injections of nicotine. Antagonists at mGlu5 receptors may therefore lead to smoking 198 
cessation 
14,15,35
. But a further study with rats showed that MPEP enhances the effect of 199 
nicotine and induces the conditioned place preference (CPP) 
38
. It was hypothesised that the 200 
effect of MPEP on the mesolimic system may induce the rewarding effect of nicotine 
38
. 201 
However, this finding differs from past studies 
14,15,35,39
. In addition, mGluR5-targeting drugs 202 
may help to prevent relapse during nicotine withdrawal. The mGluR5 NAM showed a 203 
significant potential therapeutic effect, decreasing nicotine seeking behaviour 
11,15,36
. 204 
Furthermore, mGluR5 NAM should not lead to altering mood or cognitive enhancing effects 205 
of nicotine 
37
. Similarly, preclinical studies on the effects of mGluR5 NAMs during early 206 
nicotine abstinence have shown that these drugs may worsen the somatic and depression-like 207 
symptoms of nicotine withdrawal 
15,36
. The situation of either timing or combination of 208 
mGluR5 targeting therapeutics needs further investigation. 209 
 210 
mGluR5 and nicotine addiction in humans 211 
Positron Emission Tomography (PET) radioligands like [11C]ABP688 
40
 are used in humans 212 
to assess the distribution of mGluR5 in the brain and its subsequent role in smoking addiction. 213 
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In a series of studies, the availability of mGluR5 in non-smokers, smokers and ex-smokers 214 
(abstinent for an average of 25 weeks) was investigated 
9,10
. These results provided support 215 
for markedly lower mGluR5 density in smokers. Amongst 14 smokers, global mGluR5 216 
distribution volume ratio (DVR) was 20.6% lower in the gray matter compared to 14 non-217 
smokers 
9
. Furthermore, it was found that 14 ex-smokers, had a higher mGluR5 density 218 
compared to smokers, which may be due to incomplete recovery of the receptors, especially 219 
because the ex-smokers were abstinent for only 25 weeks on average. Lower mGluR5 binding 220 
may be an adaptation to chronic increases in glutamate as a result of chronic nicotine 221 
administration (See Figure 2). In a follow-up study, 14 non-smokers, 14 smokers, 14 long-222 
term ex-smokers (abstinent for greater than 1.5 years), and 14 recent ex-smokers (abstinent 223 
for 5-12 month) were compared. Long-term ex-smokers and non-smokers showed no 224 
difference in mGluR5 binding and long-term ex-smokers showed significantly higher 225 
mGluR5 binding compared to recent ex-smokers. Seven of the recent ex-smokers were still 226 
abstinent even after one year and showed higher mGluR5 distribution volumes at baseline 227 
than relapsing participants 
10
. The effect of smoking on mGluR5 availability is strong 9,10 228 
and comparable to nicotine effects on mGluR5 in cocaine users 
41
. Here, smoking results in 229 
lower mGluR5 binding than in the cocaine using and control groups, and cocaine does not 230 
appear to affect mGluR5 binding 
41
. A similar reduction of mGluR5 binding as a result of 231 
smoking has also been shown in schizophrenia 
42
. It is suggested, that chronic nicotine abuse 232 
disturbed the homeostasis of glutamatergic transmission, and might lead - via increasing 233 
glutamate release - to a down regulation of mGluR5 density in the cortex 
9,15
.  234 
 235 
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Figure 2. Images display the average brain uptake of mGluR5 DVR in the three diagnostic 237 
groups. The brain uptake is visibly reduced in the smoker and ex-smoker group, compare with 238 
the non-smoker group (See 
9
 open access.).  239 
A current longitudinal animal study has shown the impact of chronic nicotine exposure 240 
on mGluR5 using the novel radiotracer [18F]PSS232. Here, PET shows lower [18F]PSS232 241 
binding. Furthermore, after prolonged nicotine withdrawal, [18F]PSS232 binding normalized 242 
in these rodents 
43
. These results replicate those from a previous study by the authors 
9
. 243 
However, a further study on mGluR5 binding in Major Depressive Disorder found 244 
significantly lower caudate mGluR5 DVR in smokers relative to non-smokers, although this 245 
difference did not survive correction for multiple comparisons 
29
.   246 
In summary, there is growing preclinical and clinical evidence that mGluR5 plays an 247 
important role in nicotine addiction. So far, drugs targeting mGluR5 did not show clinical 248 
utility because of lack of consistent efficacy or severe side effects. Nevertheless, findings 249 
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encourage research into therapeutic drugs targeting mGluR5 as combination therapies for 250 
patients to treat their nicotine addiction.   251 
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